CO2023012198A2 - Moduladores de sting (estimulador de genes de interferón) - Google Patents

Moduladores de sting (estimulador de genes de interferón)

Info

Publication number
CO2023012198A2
CO2023012198A2 CONC2023/0012198A CO2023012198A CO2023012198A2 CO 2023012198 A2 CO2023012198 A2 CO 2023012198A2 CO 2023012198 A CO2023012198 A CO 2023012198A CO 2023012198 A2 CO2023012198 A2 CO 2023012198A2
Authority
CO
Colombia
Prior art keywords
interferon gene
gene stimulator
sting modulators
compounds
sting
Prior art date
Application number
CONC2023/0012198A
Other languages
English (en)
Inventor
Martin James Wythes
Mehran Jalaie
Chan Woo Huh
Ketan Satish Gajiwala
Ryan Lloyd Patman
Eugene Yuanjin Rui
Jianmin Sun
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CO2023012198A2 publication Critical patent/CO2023012198A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)

Abstract

En la presente se proporcionan compuestos de la Fórmula general (I): , y sales aceptables desde el punto de vista farmacéutico de estos, procesos para la preparación de estos compuestos, composiciones que contienen estos compuestos y los usos de estos compuestos.
CONC2023/0012198A 2021-03-18 2023-09-15 Moduladores de sting (estimulador de genes de interferón) CO2023012198A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162640P 2021-03-18 2021-03-18
US202163165459P 2021-03-24 2021-03-24
PCT/IB2022/052300 WO2022195462A1 (en) 2021-03-18 2022-03-15 Modulators of sting (stimulator of interferon genes)

Publications (1)

Publication Number Publication Date
CO2023012198A2 true CO2023012198A2 (es) 2023-11-30

Family

ID=80819922

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0012198A CO2023012198A2 (es) 2021-03-18 2023-09-15 Moduladores de sting (estimulador de genes de interferón)

Country Status (17)

Country Link
US (1) US11964978B2 (es)
EP (1) EP4308563A1 (es)
JP (1) JP2024509982A (es)
KR (1) KR20230146606A (es)
AU (1) AU2022238001A1 (es)
BR (1) BR112023017731A2 (es)
CA (1) CA3213427A1 (es)
CL (1) CL2023002737A1 (es)
CO (1) CO2023012198A2 (es)
CR (1) CR20230413A (es)
DO (1) DOP2023000194A (es)
EC (1) ECSP23070418A (es)
IL (1) IL306034A (es)
MX (1) MX2023010942A (es)
TW (1) TWI829112B (es)
UY (1) UY39676A (es)
WO (1) WO2022195462A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222644A1 (en) 2022-05-18 2023-11-23 F. Hoffmann-La Roche Ag Pyrazole derivatives as sting agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
SG10201506906VA (en) 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US20190031765A1 (en) 2016-01-25 2019-01-31 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist monoclonal antibody for treating cancer
US10975287B2 (en) 2016-04-07 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
CA3024482A1 (en) 2016-05-19 2017-11-23 Bayer Aktiengesellschaft Macrocyclic indole derivatives
EP3642198B1 (en) 2017-06-22 2022-03-16 Curadev Pharma Limited Small molecule modulators of human sting
TWI741268B (zh) * 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑
WO2020028565A1 (en) * 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
PE20220166A1 (es) 2019-03-05 2022-01-28 F Star Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de enfermedad
CN114302875A (zh) 2019-05-16 2022-04-08 斯汀塞拉股份有限公司 氧代吖啶基乙酸衍生物及使用方法
AU2020355343B2 (en) 2019-09-25 2023-11-30 Pfizer Inc. Polyheterocyclic modulators of STING (stimulator of interferon genes)

Also Published As

Publication number Publication date
AU2022238001A1 (en) 2023-09-14
CA3213427A1 (en) 2022-09-22
IL306034A (en) 2023-11-01
TWI829112B (zh) 2024-01-11
KR20230146606A (ko) 2023-10-19
MX2023010942A (es) 2023-09-28
EP4308563A1 (en) 2024-01-24
UY39676A (es) 2022-10-31
US11964978B2 (en) 2024-04-23
TW202246262A (zh) 2022-12-01
WO2022195462A1 (en) 2022-09-22
BR112023017731A2 (pt) 2023-10-03
US20220306641A1 (en) 2022-09-29
CL2023002737A1 (es) 2024-04-01
CR20230413A (es) 2023-10-13
JP2024509982A (ja) 2024-03-05
ECSP23070418A (es) 2023-10-31
DOP2023000194A (es) 2023-11-30

Similar Documents

Publication Publication Date Title
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
CL2022001625A1 (es) Derivados de pirazolilo útiles como agentes anti-cancerígenos
CL2020002698A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CO2022008091A2 (es) Inhibidores de kras g12c
CO2022003321A2 (es) Moduladores de sting (estimulador de genes de interferón)
CL2020002352A1 (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
UY37007A (es) Compuestos derivados de purinas, estimuladores de genes de interferón
AR058338A1 (es) Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa.
CL2020000610A1 (es) Compuestos de bisamida que activan el sarcómero y sus usos.
DOP2021000088A (es) Compuestos de azalactam como inhibidores de hpk1
CO2023012198A2 (es) Moduladores de sting (estimulador de genes de interferón)
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
AR047922A1 (es) Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos
ECSP17069696A (es) Compuestos novedosos
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CO2022004723A2 (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CL2020001020A1 (es) Derivados de bencimidazol y sus usos.
ECSP19066134A (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
CL2020001461A1 (es) Inhibidores de dopamina–b–hidroxilasa.
ECSP18056196A (es) Derivados de indano
CL2004000630A1 (es) Compuestos derivados de oxazol; sales de dichos compuestos; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que contiene dichos compuestos; y su uso para inhibir el crecimiento tumoral.
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)
UY38133A (es) Nuevos inhibidores de cdk8/19
CO2023012196A2 (es) Compuestos cíclicos y métodos de uso